Merck KGaA has become the latest biopharma to swell its oncology pipeline with further antibody-drug conjugate (ADC) potential this week. The German company has signed up Texas’ Caris Life Sciences for a multiyear collaboration that will see targets identified by Caris and then passed to Merck for preclinical development and beyond. The April 4 release was light on details of the exact nature of these potential targets.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR™, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension.

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.

Merck MRK 0.55%increase; green up pointing triangl& Co. has struck a deal to buy Elanco ELAN 0.75%increase; green up pointing triangAnimal Health’s aqua business in a deal that expands the drugmaker’s animal-health business.

Merck & Co. has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.

First and only hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor approved for these adult patients with advanced RCC

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved WELIREG, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases

RAHWAY, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics for a total potential consideration of up to $610 million, including an undisclosed upfront payment as well as contingent milestone payments.

Lynparza can now be used in combination with Johnson & Johnson’s Zytiga and a corticosteroid to treat patients with mCRPC whose tumors have BRCA mutations.